​

Keros Therapeutics Ownership | Who Owns Keros Therapeutics?

OverviewForecastRevenueFinancialsChart

Keros Therapeutics Ownership Summary

Keros Therapeutics is owned by 26.50% institutional investors, 3.63% insiders, and 69.87% retail investors. Adar1 capital management is the largest institutional shareholder, holding 13.27% of KROS shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.37% of its assets in Keros Therapeutics shares.

KROS Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKeros Therapeutics26.50%3.63%69.87%
SectorHealthcare Stocks 232.63%10.66%-143.29%
IndustryBiotech Stocks 382.12%10.42%-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Adar1 capital management5.39M13.27%$85.26M
Blackrock2.51M8.53%$114.86M
Madison avenue partners, lp2.71M6.67%$42.84M
Blackrock funding, inc. /de2.29M5.64%$46.64M
Vanguard group1.53M3.75%$31.06M
Tang capital management1.42M3.49%$22.45M
State street1.30M3.21%$20.61M
Orbimed advisors1.02M2.51%$16.12M
Millennium management878.16K2.43%$13.90M
Alkeon capital management850.51K2.09%$13.46M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Adar1 capital management5.39M8.01%$85.26M
Rangeley capital258.62K3.54%$4.09M
Madison avenue partners, lp2.71M2.56%$42.84M
Superstring capital management lp95.08K1.48%$1.50M
Logos global management lp850.00K1.21%$13.45M
Monimus capital management, lp108.05K1.05%$1.71M
Tang capital management1.42M0.86%$22.45M
Redmile group552.51K0.85%$8.74M
Orbimed advisors1.02M0.38%$16.12M
Pdt partners332.81K0.33%$5.27M

Top Buyers

HolderShares% AssetsChange
Renaissance591.69K0.02%436.99K
Blackrock2.51M0.00%347.23K
Millennium management878.16K0.01%305.17K
Qube research303.12K0.01%264.44K
Hrt financial lp260.89K0.02%218.09K

Top Sellers

HolderShares% AssetsChange
Western standard---2.19M
Braidwell lp---1.89M
Darwin global management---1.69M
Holocene advisors, lp---1.20M
Vanguard group1.53M0.00%-1.19M

New Positions

HolderShares% AssetsChangeValue
Bessemer group143.85K0.00%143.85K$2.93M
Superstring capital management lp95.08K1.48%95.08K$1.50M
Norges bank64.90K0.00%64.90K$1.03M
Empowered funds60.08K0.01%60.08K$1.22M
Massachusetts financial services co /ma/43.70K0.00%43.70K$889.63K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-4.00
Riggs asset managment-5.00
Point72 asset management-6.00
J.safra asset management-8.00
National bank of canada /fi/-10.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025102-36.65%10,764,752-69.51%260.35%46-45.88%412.50%
Sep 30, 202515312.50%34,356,9504.91%841.30%801.27%3918.18%
Jun 30, 2025143-13.86%35,921,6664.01%881.22%82-14.58%35-7.89%
Mar 31, 2025169-2.87%36,741,515-0.02%900.87%98-14.04%3822.58%
Dec 31, 2024168-1.75%35,057,5030.30%971.04%11014.58%30-34.78%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF960.39K2.37%1.20K
iShares Russell 2000 ETF699.69K2.30%341.17K
Fidelity Select Health Care820.00K2.02%20.00K
Vanguard Total Stock Mkt Idx Inv595.32K1.95%-
State Street® SPDR® S&P® Biotech ETF519.06K1.70%-2.80K
SPDR® S&P Biotech ETF661.47K1.63%1.48K
ACAP Strategic A419.59K1.38%-
Fidelity Advisor Health Care I500.00K1.23%15.00K
Federated Hermes MDT SCC Institutional364.44K1.20%-
Federated Hermes MDT Small Cap Core IS364.44K1.20%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 09, 2026BIENAIME JEAN JACQUES-Buy$22.42K
Feb 19, 2026Seehra Jasbir CHIEF EXECUTIVE OFFICERSell$113.43K
Feb 18, 2026Lerner Lorena Raquel Chief Science OfficerSell$63.32K
Feb 18, 2026Cho Esther SVP, General CounselSell$77.58K
Feb 18, 2026Regnante Keith CHIEF FINANCIAL OFFICERSell$77.48K

Insider Transactions Trends

DateBuySell
2026 Q114
2025 Q4-2
2025 Q3--
2025 Q25-
2025 Q1--

KROS Ownership FAQ

Who Owns Keros Therapeutics?

Keros Therapeutics shareholders are primarily institutional investors at 26.50%, followed by 3.63% insiders and 69.87% retail investors. The average institutional ownership in Keros Therapeutics's industry, Biotech Stocks , is 382.12%, which Keros Therapeutics falls below.

Who owns the most shares of Keros Therapeutics?

Keros Therapeutics’s largest shareholders are Adar1 capital management (5.39M shares, 13.27%), Blackrock (2.51M shares, 8.53%), and Madison avenue partners, lp (2.71M shares, 6.67%). Together, they hold 28.47% of Keros Therapeutics’s total shares outstanding.

Does Blackrock own Keros Therapeutics?

Yes, BlackRock owns 8.53% of Keros Therapeutics, totaling 2.51M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 114.86M$. In the last quarter, BlackRock increased its holdings by 347.23K shares, a 16.03% change.

Who is Keros Therapeutics’s biggest shareholder by percentage of total assets invested?

Adar1 capital management is Keros Therapeutics’s biggest shareholder by percentage of total assets invested, with 8.01% of its assets in 5.39M Keros Therapeutics shares, valued at 85.26M$.

Who is the top mutual fund holder of Keros Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Keros Therapeutics shares, with 2.37% of its total shares outstanding invested in 960.39K Keros Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools